Provided by Tiger Trade Technology Pte. Ltd.

AI Healthcare

709.39
-22.8418-3.12%
Number of Gainers:- -
Number of Losers:4
Number of Flat:- -
PE:- -
High:735.36
Open:723.48
Low:706.95
Close:732.23
Volume:53.76M
Turnover:965.69M
Market Cap:22.68B
Float Cap:17.47B

Loading ...

Top Recursion Pharma Insider Makes a Major Move With His Shares

TIPRANKS
·
1 hour ago

Cathie Wood’s ARK Investment buys 1.9M shares of Recursion Pharmaceuticals today

TIPRANKS
·
3 hours ago

Recursion Director Robert Hershberg Sells 25,000 Common Shares for $125,000

Reuters
·
5 hours ago

Moderna, Merck Climb on Collaboration with Tempus

Reuters
·
11 hours ago

Tempus AI announces multi-year collaboration with Moderna, Merck

TIPRANKS
·
Yesterday

Tempus Expands Multi-Year Collaboration with Moderna, Merck on V940 Melanoma Vaccine Commercialization Support

Reuters
·
Yesterday

Tempus - Announces Expanded Multi-Year Collaboration for Intismeran Autogene Commercialization

THOMSON REUTERS
·
Yesterday

Tempus: to Also Provide Ngs Services to Support Intismeran Autogene Design and Manufacturing Process

THOMSON REUTERS
·
Yesterday

Tempus: to Manage Collection & Transfer of Tumor Tissue & Blood Samples Needed for Next-Generation Sequencing

THOMSON REUTERS
·
Yesterday

Tempus - Financial Terms of Collaboration not Disclosed

THOMSON REUTERS
·
Yesterday

Tempus Announces Multi-Year Collaboration with Moderna and Merck

THOMSON REUTERS
·
Yesterday

Personalis-Tempus AI Deal Clears US Antitrust Waiting Period Under HSR Act

Reuters
·
Yesterday

Personalis Slips as BTIG Downgrades, Sees no Rival Bid for Tempus Deal

Reuters
·
Oct 06

Cathie Wood’s ARK Investment buys 1.5M shares of Recursion Pharmaceuticals today

TIPRANKS
·
Oct 06

NASD Most Active Issues

Dow Jones
·
Oct 06

Tempus AI Inc Stock (TEM) Closed Up by 9.03% on Oct 5: Drivers Behind the Movement

TradingKey
·
Oct 06

Could Tempus RNA License Alter The Investment Case For Recursion Pharmaceuticals (RXRX)?

Simply Wall St.
·
Oct 03

Beam Therapeutics (BEAM) Could Be 52% Undervalued Following Its Lawsuit Over Research Misuse

Simply Wall St.
·
Oct 03

Crispr Therapeutics Presents Phase 1 Zugo-Cel Data in Refractory Systemic Sclerosis at ACR Convergence 2026

Reuters
·
Oct 02

CRISPR Therapeutics (CRSP) Stock May Command A Premium On Its Equity Base

Simply Wall St.
·
Oct 02